Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 92 filers reported holding Y-MABS THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $482,486 | -67.2% | 98,870 | -3.0% | 0.08% | -66.5% |
| Q3 2022 | $1,470,000 | -6.8% | 101,970 | -2.1% | 0.22% | 0.0% |
| Q2 2022 | $1,577,000 | +24.4% | 104,200 | -2.4% | 0.22% | +63.5% |
| Q1 2022 | $1,268,000 | -65.4% | 106,770 | -52.8% | 0.14% | -62.6% |
| Q4 2021 | $3,666,000 | -71.6% | 226,180 | -50.0% | 0.37% | -68.8% |
| Q3 2021 | $12,903,000 | -34.6% | 452,110 | -22.5% | 1.17% | -34.1% |
| Q2 2021 | $19,723,000 | +28.4% | 583,508 | +14.8% | 1.78% | +24.0% |
| Q1 2021 | $15,364,000 | +41.4% | 508,083 | +131.6% | 1.44% | +36.5% |
| Q4 2020 | $10,863,000 | – | 219,419 | – | 1.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,271,000 | 2.63% |
| Sofinnova Investments, Inc. | 2,194,278 | $26,068,000 | 1.98% |
| MPM BioImpact LLC | 443,702 | $5,271,000 | 1.42% |
| Soleus Capital Management, L.P. | 238,982 | $2,839,000 | 0.37% |
| Lombard Odier Asset Management (Switzerland) SA | 221,774 | $2,635,000 | 0.21% |
| Artal Group S.A. | 400,000 | $4,752,000 | 0.20% |
| Polar Capital Holdings Plc | 2,877,671 | $34,187,000 | 0.15% |
| ASHFORD CAPITAL MANAGEMENT INC | 106,770 | $1,268,000 | 0.14% |
| Cormorant Asset Management, LP | 150,000 | $1,782,000 | 0.14% |
| Virtus ETF Advisers LLC | 23,646 | $281,000 | 0.13% |